OncoCyte Corporation (OCX)
NASDAQ: OCX · Real-Time Price · USD
3.060
-0.150 (-4.67%)
Mar 31, 2025, 4:00 PM EDT - Market closed
OncoCyte Revenue
In the year 2024, OncoCyte had annual revenue of $1.88M with 25.15% growth. OncoCyte had revenue of $1.49M in the quarter ending December 31, 2024, with 373.25% growth.
Revenue (ttm)
$1.88M
Revenue Growth
+25.15%
P/S Ratio
21.26
Revenue / Employee
$38,388
Employees
49
Market Cap
87.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
Dec 31, 2020 | 1.22M | - | - |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
OCX News
- 7 days ago - OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 - GlobeNewsWire
- 6 weeks ago - Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - GlobeNewsWire
- 2 months ago - Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - GlobeNewsWire
- 3 months ago - Oncocyte Expands Market Opportunity for VitaGraft™ Kidney - GlobeNewsWire
- 4 months ago - OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 - GlobeNewsWire
- 5 months ago - Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - GlobeNewsWire